Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans

J Antimicrob Chemother. 2002 Mar;49(3):525-9. doi: 10.1093/jac/49.3.525.

Abstract

We established a reproducible lethal disseminated infection by the opportunistic fungus Scedosporium prolificans in an immunosuppressed murine model. We compared the effectiveness of the combined administration of liposomal amphotericin B (LAMB) and granulocyte colony-stimulating factor (G-CSF) with that of either agent alone and with that of amphotericin B deoxycholate (AMB). LAMB + G-CSF and LAMB treatments improved survival significantly with respect to the untreated control. The mean survival times of these three groups were 13.2, 9.1 and 7.9 days, respectively. Culture results in terms of colony counts for samples of deep organs were lower in mice treated with the combined therapy, although differences were not significant. Combined LAMB + G-CSF therapy could be a promising approach for the treatment of disseminated infections of S. prolificans, although further studies are required to determine the most appropriate doses.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / therapeutic use*
  • Animals
  • Antifungal Agents / therapeutic use*
  • Colony Count, Microbial
  • Disease Models, Animal
  • Drug Therapy, Combination
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Humans
  • Immunosuppression
  • Liposomes
  • Male
  • Mice
  • Mice, Inbred Strains
  • Mycoses / drug therapy*
  • Mycoses / mortality
  • Opportunistic Infections / drug therapy*
  • Opportunistic Infections / mortality
  • Recombinant Proteins
  • Scedosporium / drug effects*
  • Scedosporium / isolation & purification
  • Survival Rate

Substances

  • Antifungal Agents
  • Liposomes
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Amphotericin B